Microbubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer

2024

Microbubble-Protected Oncolytic Virotherapy for Breast Cancer

Sample size: 48 publication 10 minutes Evidence: high

Author Information

Author(s): Sitta Juliana, De Carlo Flavia, Kirven Imani, Tackett John H., Penfornis Patrice, Dobbins George Clement, Barbier Mallory, Del Valle Luis, Larsen Clayton T., Schutt Ernest G., Li Rhodemann, Howard Candace M., Claudio Pier Paolo

Primary Institution: University of Mississippi Medical Center

Hypothesis

Can microbubble-protected oncolytic virotherapy enhance tumor necrosis and T-lymphocyte infiltration in triple-negative breast cancer?

Conclusion

The study demonstrated that microbubble-protected oncolytic virotherapy significantly increased tumor necrosis and T-lymphocyte infiltration in a mouse model of triple-negative breast cancer.

Supporting Evidence

Microbubble/virus complexes led to significantly greater tumor necrosis compared to controls.
CD8+ T-lymphocyte infiltration was significantly higher in treated tumors.
A low CD4+/CD8+ TIL ratio was observed in treated tumors, indicating a favorable immune response.
An abscopal effect was noted in untreated tumors on the opposite flank.
Statistically significant differences in tumor size/necrosis ratios were found between treatment groups.

Takeaway

Researchers found that using tiny bubbles to deliver cancer-fighting viruses helped shrink tumors and attract immune cells in mice with breast cancer.

Methodology

The study used humanized mice with triple-negative breast cancer, treated with microbubble/virus complexes and assessed tumor size and immune cell infiltration.